Related references
Note: Only part of the references are listed.Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib
Noelia Purroy et al.
BLOOD (2022)
The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
Tadeusz Robak et al.
CANCERS (2022)
The Mysterious Actor-γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
Michal K. Zarobkiewicz et al.
CELLS (2022)
A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia
Agnieszka Goral et al.
FRONTIERS IN IMMUNOLOGY (2022)
Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependen and outcome-specific manners
Byeongho Jung et al.
JCI INSIGHT (2022)
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
Saar Gill et al.
BLOOD ADVANCES (2022)
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Eμ-TCL1 mice
Bola S. Hanna et al.
HAEMATOLOGICA (2021)
Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients
Fuli Fan et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy
Sundee Dees et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword
Elisavet Vlachonikola et al.
FRONTIERS IN IMMUNOLOGY (2021)
Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively
Carol Moreno et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
Joanne E. Davis et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
Fleur S. Peters et al.
HAEMATOLOGICA (2021)
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia
Isabelle G. Solman et al.
LEUKEMIA RESEARCH (2021)
Acalabrutinib in treatment-naive chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2021)
T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
Palak H. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2021)
Targeting the tumor microenvironment in chronic lymphocytic leukemia
Rebecka Svanberg et al.
HAEMATOLOGICA (2021)
Current and future treatment strategies in chronic lymphocytic leukemia
Krish Patel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Nitin Jain et al.
LEUKEMIA (2021)
Mucosal Associated Invariant T Cells in Cancer-Friend or Foe?
Chloe O'Neill et al.
CANCERS (2021)
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
Maria Cristina Puzzolo et al.
FRONTIERS IN ONCOLOGY (2021)
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL
Maissa Mhibik et al.
BLOOD (2021)
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Yingyue Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
Rula Zain et al.
FRONTIERS IN IMMUNOLOGY (2021)
T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia
Elisavet Vlachonikola et al.
CANCERS (2021)
Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL
Lauren Elston et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Tuning T helper cell differentiation by ITK
Jessica P. Elmore et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2020)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis
Vincenza Simona Delvecchio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
Maissa Mhibik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions
Francesca Arruga et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL
Andre F. Rendeiro et al.
NATURE COMMUNICATIONS (2020)
CAR-T and ibrutinib vs CLL: sequential or simultaneous?
Arnon P. Kater et al.
BLOOD (2020)
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C. Byrd et al.
CLINICAL CANCER RESEARCH (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Philipp M. Roessner et al.
LEUKEMIA (2020)
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
Margaux Lejeune et al.
FRONTIERS IN IMMUNOLOGY (2020)
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia
Isabelle G. Solman et al.
LEUKEMIA RESEARCH (2020)
Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles
Nathan Dubois et al.
FRONTIERS IN ONCOLOGY (2020)
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
Valentina Griggio et al.
FRONTIERS IN IMMUNOLOGY (2020)
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
Sarah Cadot et al.
BIOMARKER RESEARCH (2020)
Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients
Tanya Siddiqi et al.
BLOOD (2020)
Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
Bola S. Hanna et al.
LEUKEMIA (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Chronic lymphocytic leukaemia: the role of T cells in a B cell disease
Stephen Man et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Genetic Deficiency and Biochemical Inhibition of ITK Affect Human Th17, Treg, and Innate Lymphoid Cells
Ahmet Eken et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2019)
Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia
Federico Gaiti et al.
NATURE (2019)
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
Richard Lemal et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
Meixiao Long et al.
BLOOD (2019)
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib
Eman L. Dadashian et al.
CANCER RESEARCH (2019)
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia
Helen M. Parry et al.
FRONTIERS IN IMMUNOLOGY (2019)
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Farrukh T. Awan et al.
BLOOD ADVANCES (2019)
Regulatory T-cells drive immune dysfunction in CLL
Deepesh Lad et al.
LEUKEMIA & LYMPHOMA (2018)
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
Hannah R. Robinson et al.
BLOOD (2018)
CD38-NAD(+)Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
Shilpak Chatterjee et al.
CELL METABOLISM (2018)
When worlds collide: Th17 and Treg cells in cancer and autoimmunity
Hannah M. Knochelmann et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Immune failure, infection and survival in chronic lymphocytic leukemia
Kyle R. Crassini et al.
HAEMATOLOGICA (2018)
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Christopher Pleyer et al.
LEUKEMIA & LYMPHOMA (2018)
Immune failure, infection and survival in chronic lymphocytic leukemia
Kyle R. Crassini et al.
HAEMATOLOGICA (2018)
Molecular Determinants of Target Cell Recognition by Human γδ T Cells
Andre E. Simoes et al.
FRONTIERS IN IMMUNOLOGY (2018)
Improving CLL V gamma 9V delta 2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib
Iris de Weerdt et al.
BLOOD (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia
Maria Joao Baptista et al.
BLOOD (2018)
Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial
Despoina Papazoglou et al.
BLOOD (2018)
Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All
Bijal Shah et al.
TRENDS IN CANCER (2018)
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Marzia Palma et al.
HAEMATOLOGICA (2017)
Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements
A. Vardi et al.
LEUKEMIA (2017)
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Marzia Palma et al.
HAEMATOLOGICA (2017)
Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
Martijn H. A. van Attekum et al.
HAEMATOLOGICA (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
Qingsong Yin et al.
JOURNAL OF IMMUNOLOGY (2017)
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood
T. M. Herndon et al.
LEUKEMIA (2017)
Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia
Vassiliki E. Mpakou et al.
LEUKEMIA RESEARCH (2017)
Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number
Monika Podhorecka et al.
ONCOTARGET (2017)
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia
Noelia Purroy et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
Martijn H. A. van Attekum et al.
HAEMATOLOGICA (2017)
Natural Killer T Cells in Cancer immunotherapy
Shiny Nair et al.
FRONTIERS IN IMMUNOLOGY (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis
Francesca Gorini et al.
BLOOD (2017)
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib
Jan A. Burger et al.
JCI INSIGHT (2017)
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
Elisa ten Hacken et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas
Hsu-Ping Kuo et al.
BLOOD (2016)
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
Fabienne McClanahan et al.
BLOOD (2015)
Perturbation of the normal immune system in patients with CLL
Francesco Forconi et al.
BLOOD (2015)
The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia
Mehdi Yousefi et al.
FUTURE ONCOLOGY (2015)
An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia
Morgan E. Wallace et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias
Deepesh P. Lad et al.
LEUKEMIA & LYMPHOMA (2015)
Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response
Yonglian Sun et al.
SCIENCE SIGNALING (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response
Yonglian Sun et al.
SCIENCE SIGNALING (2015)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia
Anne Rissiek et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Toll-like receptors in the pathogenesis of human B cell malignancies
Johana M. Isaza-Correa et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
S. E. M. Herman et al.
LEUKEMIA (2014)
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
Jan A. Burger et al.
SEMINARS IN CANCER BIOLOGY (2014)
Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor lbrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma
Jan A. Burger et al.
BLOOD (2014)
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
John C. Riches et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
The who's who of T-cell differentiation: Human memory T-cell subsets
Yolanda D. Mahnke et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
Davide Brusa et al.
HAEMATOLOGICA (2013)
Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
Iwona Hus et al.
PLOS ONE (2013)
B-cell receptor signaling as a driver of lymphoma development and evolution
Carsten U. Niemann et al.
SEMINARS IN CANCER BIOLOGY (2013)
Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia
Farhad Jadidi-Niaragh et al.
TUMOR BIOLOGY (2013)
The integration of T cell migration, differentiation and function
David Masopust et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression
Claudia Nunes et al.
CLINICAL CANCER RESEARCH (2012)
Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance
Preetesh Jain et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
Davide Bagnara et al.
BLOOD (2011)
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease
Giovanni D'Arena et al.
LEUKEMIA RESEARCH (2011)
Natural killer-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: Intracellular cytokine expression and relationship with clinical outcome
Agnieszka Bojarska-Junak et al.
ONCOLOGY REPORTS (2010)
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Jan A. Burger et al.
BLOOD (2009)
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia
Andrea Buerkle et al.
BLOOD (2007)
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α
M Nishio et al.
BLOOD (2005)
Signaling through ltk promotes T helper 2 differentiation via negative regulation of T-bet
AT Miller et al.
IMMUNITY (2004)
Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia
MR Rezvany et al.
BLOOD (2003)
Share Paper
